OTCPicks.com Daily Market Movers Digest Midday Report f

9/17/2009 12:21 PM

Penny Stocks by: OTC Picks

Buy AEXP Online for $0. Trade stocks for free on Zecco.com.

OTCPicks.com Daily Market Movers Digest Midday Report for Thursday,
September 17th AEXP, DVME, MDOR, MPPC, EWRC, SPDE, IOPM, HYTM, SEED, LLBO,
ALRT

Our Stocks to Watch today include American Exploration Corp. (OTCBB:
AEXP), Diverse Media Group Inc. (OTC: DVME), Magnum d`Or Resources Inc.
(OTCBB: MDOR), myPhotopipe.com Inc. (OTC: MPPC), eWorld Companies Inc.
(OTC: EWRC), Speedus Corp. (Nasdaq: SPDE), IntraOp Medical Corp. (OTCBB:
IOPM), Hythiam Inc. (Nasdaq: HYTM), Origin Agritech Ltd. (Nasdaq: SEED),
Lifeline Biotechnologies Inc. (OTC: LLBO) and ALR Technologies Inc. (OTCBB:
ALRT).

Visit to register for our Daily Market Movers Digest Newsletter and Email
Stock Watch Alerts.

AMERICAN EXPLORATION CORPORATION (OTCBB: AEXP)
"Up 42.86% in morning trading"

Detailed Quote:

Company Profile:

American Exploration Corp. is engaged in the exploration and development
of oil and gas prospects with the potential for discovery of new or
unconventional hydrocarbon resources in the continental United States.

AEXP News:

September 17 - American Exploration Corp. and Mainland Resources, Inc.
Enter Into Letter Agreement to Jointly Develop Mississippi Acreage

American Exploration Corp. (OTCBB: AEXP) (Frankfurt: EQO), a Nevada
company ("the Company"), and Mainland Resources, Inc. (OTCBB: MNLU)
(Frankfurt: 5MN) have entered into a Letter Agreement to jointly develop
their contiguous acreage in Mississippi.

American Exploration will commit approximately 5000 net acres to the
project and Mainland Resources will commit approximately 8500 net acres.
This represents a total of 13,500 net acres to the composite project area.

Mainland Resources will act as the Operator of the project area and has
agreed to pay 80% of the initial well (drilling and completion costs) for a
51% working interest in the well and total project area. American
Exploration will pay 20% of the initial well (drilling and completion
costs) to earn a 49% working interest in the well and total project area.
The additional costs (ie. drilling, completions etc.) for oil and gas
activities on the 13,500 net acre project area will be split on a 49% / 51%
basis between American and Mainland respectively.

Mainland has a proven track record in the Haynesville shale having
participated in the drilling and completion of two producing wells and a
third well that is slated for completion on its lands in DeSoto Parish in
Northwest Louisiana.

Company President Steve Harding states, "Working with Mainland Resources,
Inc. is an ideal situation for American Exploration. They have had great
success in the Haynesville shale in Louisiana and with our combined land
position, we have secured enormous upside for our company on this
exceptional prospect. We welcome the opportunity and look forward to moving
into the drilling stage."

DIVERSE MEDIA GROUP INCORPORATED (OTC: DVME)
"Up 14.29% in morning trading"

Detailed Quote:

Company Profile:

Diverse Media Group, Inc. (OTC: DVME) is an entertainment company that
aggregates expertise across all aspects of the media industry. Diverse
Media Group has at its core the established 27-year history of its wholly
owned subsidiary, Diverse Talent Group. Diverse Talent Group is now the
10th largest Hollywood agency offering talent and literary representation
in commercials, episodic television, cable programming and motion pictures.
The company has the ability to create programming, foster distribution and
represent talented individuals to fuel a new digital age of content
generation. The parent company also includes the subsidiary Talent Quest
America, Inc., which identifies new and rising talent representing the
future of the Hollywood entertainment community.

DVME News:

September 16 - Diverse Media Group Inc. (DVME) Finalizes Joint Venture to
Create Celebrity Superhero Franchises

Diverse Media Group, Inc. (OTC: DVME) has completed the acquisition of a
50% equity interest in Celebrities in Action, Inc. (CIA) in a joint
venture to create new superhero character franchises based on real-life
Hollywood celebrities. The new characters will be developed with major
stars of film, music, television and sports. Plans include original
storylines spanning television, film, mobile and home entertainment, video
games, publishing, consumer products and merchandising.

Celebrities In Action, Inc. is a vertically integrated entertainment
company that develops, produces and distributes proprietary and licensed
entertainment content, with a particular focus on animated celebrities.

Diverse Media Group purchased 37,500,000 shares of CIA common stock,
representing 50% of all authorized shares of Celebrities In Action, Inc. In
exchange, Diverse Media Group agreed to assume CIA`s responsibilities in
signing up celebrities and/or well-known athletes to participate in the
creative joint venture with Stan Lee`s POW! Entertainment, Inc. Diverse
Media Group also agreed to issue 20,400 shares of its Series A Preferred
Stock to Fordee CA Trust, the majority CIA shareholder, exchanged for the
acquisition of California PA Trust, a California business trust owned by
Fordee, and Fordees release of its option to acquire the 37,500,000
shares of common stock in CIA.

CIA has an existing joint venture with Stan Lees POW! Entertainment
banner to develop, produce and distribute animated programming, content and
merchandise based on the premise of real-life celebrities in competition
against characters from other worlds. Diverse Media Group will identify and
secure the celebrity participation and Stan Lee will provide the creative
vision to shape these novel superhero personas.

Praised as a legend worldwide and honored with his own Hasbro
Marvel Legends action figure, Stan Lee is associated with such
breakthrough superhero characters as Spider-Man, The Incredible Hulk,
The Fantastic Four, X-Men, Iron Man and Daredevil. He is also
recognized as an innovator in creating new media opportunities and revenue
streams for the superhero genre. Among his accomplishments, Stan Lee is
credited with leading the expansion of Marvel Comics from a small division
of a publishing house to a multimedia corporation, and developing his
characters into longstanding franchises.

Hollywood talent agent Chris Nassif, founder of Diverse Talent Group and
its parent company, Diverse Media Group, Inc., commented, Stan Lee has
excelled as a visionary, a leader in the global media industry and a
creative talent whose complex fictional characters have become living,
breathing members of our world. We are delighted to provide the setting for
him to create characters based on real stars, which taps into the resources
of CIA, POW! Entertainment, and Diverse Media Group.

Lees POW! Entertainment company has a first-look deal with Disney,
which last month acquired his former company, Marvel Comics, for $4
Billion.

MAGNUM D`OR RESOURCES (OTCBB: MDOR)

Detailed Quote:

Company Profile:

Magnum d`Or Resources, Inc. focuses in operating in recycling and waste
management sectors. It intends to develop facilities that produce rubber
powders, thermoplastics, and thermoplastics elastomers. Magnum holds
licensing rights to various patents that would allow rubber to be
devulcanized, specialty blend EPDM powders, and EPDM compounds. The company
was founded in 1999 and is based in Ft. Lauderdale, Florida.

MDOR News:

September 17 - Emerging Stock Report Initiates Independent Research
Coverage on Magnum d`Or Resources Inc.

Emerging Stock Report, a leading provider of sector specific independent
investment research, initiated coverage on Magnum d`Or Resources Inc.
(OTCBB: MDOR). Emerging Stock Report is currently offering a complimentary
trial subscription. To view the company`s research, go to
www.emergingstockreport.com.

September 16 - Greentech International Advisors Announces Shareholder
Update for MDOR and Releases Key Data on New Positive Developments

Greentech International Advisors, Inc announces key data on Magnum D`Or
Resources, Inc. (OTCBB: MDOR), a next generation rubber recycling solutions
company. Recent news headlines regarding MDOR have claimed major property
acquisitions as well advancements entailing revolutionary custom compounds
and their uses worldwide; such claims have attracted a significant number
of international investors and caused an increase in liquidity and
appreciation of share price. Therefore, and due to many recent developments
Greentech, would like to announce the following:

First, Greentech has been in contact and negotiations with large financial
institutions regarding establishing strong equity positions in MDOR. The
results of such contacts will be revealed as well as the identities of such
institutions in the very near future and upon completion of all necessary
documentation.

Second, Greentech has received many enquiries regarding the current
filming of the Magog and Colorado operations, which is will to be aired
worldwide. The shoot has already commenced (view here) and will be
completed on Sept 17th, 2009, followed by editing. Greentech will be
announcing the dates of the airing within the next two weeks. View more
info on the 2 upcoming MDOR TV Series (click here).

Third, that Magnum SRI is currently in possession of the test results for
the Revolutionary Light Truck Custom Compound and will release the results
publicly by or before Sept 19th, 2009.

Fourth, Magnum will be updating the market with some new positive
developments in the next two weeks, regarding its progress in relation to
engineering, equipment and operation of its newly acquired 120+ acre
facility and tire landfill in Hudson, Colorado.

Greentech is very excited to be involved with Magnum and is looking
forward to the exciting weeks ahead. Moreover, Greentech is confident that
the weeks to come will unveil more substantial achievements and positive
news which will significantly advance Magnum and position it as a world
leader in the market of recycled tires, rubber, and compounds.

MYPHOTOPIPE.COM INCORPORATED (OTC: MPPC)

Detailed Quote:

Company Profile:

MyPhotopipe.com Inc. is a US-based provider of online digital photo
processing and related services catering to high-end amateur and
professional photographers. The Companys primary web portal is
www.myphotopipe.com. Its services include photo finishing and printing,
online sharing, photo books, digital photo templates, and online hosting
and selling of photographs. The Company provides services to more than
18,500 professional and high-end amateur photographers nationwide; more
than 190,000 copies of its software have been downloaded and are in use.

MPPC News:

September 16 - myPhotopipe.com Launches Technology Platforms for Retail
and Commercial Users

myPhotopipe.com, Inc. (OTC: MPPC) announced the completion of a suite of
online digital photo tools that will allow retailers and other vendors to
seamlessly integrate with the Company`s photo print lab and purchase print
processing services.

"This is huge for us and for our customers," stated Darren Schiff, Chief
Operating Officer of myPhotopipe.com, Inc. "There are hundreds of web sites
and retailers that offer prints to their customers. Until now, they had
few, if any, options for high quality print fulfillment and were literally
forced to work with high-volume, low-end processors. That doesn`t work if
quality is the name of the game and better quality prints are in high
demand. These companies can now access our professional lab for back-end
fulfillment, using an entirely automated suite of web-based tools. They get
professional prints at competitive prices and are able to seamlessly access
the capabilities of a professional lab. We believe we are the first
professional lab to offer this level of integration."

Schiff estimated that the Company`s new Application Programming Interface
("API") will allow myPhotopipe.com to compete for the tens of millions of
dollars that are currently funneled to print processors through independent
front-end retailers and photo hosting sites. "Because prints are family
treasures that last a lifetime, quality has become a defining feature,"
noted Schiff. "By writing to our API, we provide these retailers with
access to high quality, professional services and the finest prints in the
nation. The retailers own the customers. We handle the fulfillment.
Everyone wins."

The Company`s proprietary API allows myPhotopipe.com to serve as the
back-end provider to any web site or retailer that offers prints to its
customers. This includes fashion sites that provide composition prints for
models, sites used by professional photographers to sell "event" photos,
and countless others that earn revenues for the processing of digital
photos into prints.

Schiff expects an incremental revenue bump from the onset, with the
potential to double corporate revenues though API services. "It`s all about
servicing the digital age with better features and a professional back-end
product," said Schiff. "We expect to announce our first customer for this
service within the next few weeks."

EWORLD COMPANIES INCORPORATED (OTC: EWRC)

Detailed Quote:

Company Profile:

eWorld Companies, Inc. is an online marketing & advertising technologies
company that develops and markets cutting edge technologies using rich
media, flash, animation and 3D graphics to help individuals and businesses
market and advertise online. eWorld`s revenue model consists of seven
components: (1) Affiliation Fees, (2) Affiliate Monthly Subscriptions, (3)
Affiliate Benefit Subscriptions, (4) Product Sales, (5) Advertising
Revenues, (6) Web Development Accounts, and (7) International Licensing
Fees.

EWRC News:

September 17 - CEO Henning Morales Goes to Washington D.C. and Kicks Off
Sponsorship Alliance With National Hispanic Foundation for the Arts at Gala
Event Where Supreme Court Justice Sonia Sotomayor Was Special Guest

eWorld Companies, Inc. (OTC: EWRC) and the National Hispanic Foundation
for the Arts have agreed to a series of cross-promotional efforts to
promote one another`s activities and charitable causes. The program got
under way this week in Washington, D.C. when eWorld was presented Monday
evening at a VIP Salon Dinner and Tuesday night at the Foundation`s Annual
Gala. This year`s gala was themed "Noche Musical" to help launch "Latin
Music USA," a four-part PBS documentary airing next month, and the guest
list included a veritable "Who`s who" of insiders from Washington, Wall
Street and the entertainment industry including special guest new Supreme
Court Justice Sonia Sotomayor. Others in attendance included Secretary of
Labor Hilda Solis, FCC Chairman Julius Genachowski, Executive Director of
the President`s Commission on the Arts & Humanities Rachel Goslins, and a
wide range of A-list celebrities, politicos, and executives including
representatives from NBC Universal, Disney/ABC, Fox Entertainment, CBS
Corporation, Ford Motor Company, AT&T, The Coca-Cola Company and others.
eWorld was represented by CEO Henning Morales and Sr. VP Don Grenough, and
video footage and still photos of the event will be available soon on
eWorld`s Boomerang Media Station.

eWorld and NHFA will continue to work together on a series of additional
activities, including eWorld`s sponsorship of a special fund-raising event
for NHFA`s charitable causes, which will take place in Los Angeles during
Grammys week, in conjunction with the eWorld Music Awards Show on January
29, 2010.

The NHFA was co-founded by Jimmy Smits, Sonia Braga, Esai Morales, Merel
Julia (widow of Raul Julia), and Washington, D.C. attorney Felix Sanchez,
to increase participation of Hispanics in the entertainment industry. The
Foundation offers graduate scholarships and an outreach program at
prominent colleges and universities for young Latinos aspiring to careers
in entertainment and media. It also seeks to expand career opportunities
for existing talent in all aspects of entertainment, telecommunications and
performing arts.

SPEEDUS CORPORATION (NASDAQ: SPDE)
"Up 140.62% in morning trading"

Detailed Quote:

Speedus Corp., through its subsidiaries, engages in healthcare,
restaurant, and wireless businesses in the United States. The company has
co-invested with Siemens Corporate Research, Inc., a subsidiary of Siemens
Corporation, in Zargis Medical Corp. to develop advanced diagnostic
decision support products and services that automatically analyze
acoustical data from a patient to determine physiologically significant
features useful in medical diagnosis for primary care physicians,
pediatricians, cardiologists, and other healthcare professionals. It owns
90% of F&B Gudtfood, the creator and operator of the original Eurocentric
cafe, which operates a store in Manhattan. The company has a portfolio of
patents that provide high-speed wireless communication systems. In
addition, it offers Local Multipoint Distribution Service (LMDS) license
for developing and deploying LMDS technology that is used for various fixed
wireless purposes, including wireless local loop telephony, high-speed
Internet access, and two-way teleconferencing. The company, formerly known
as SPEEDUS.COM, Inc., was founded in 1995 and is based in New York, New
York.

SPDE News:

September 17 - Zargis Receives FDA Clearance for Signal X6 Telemedicine
Device; OK Allows Delivery to US Army

Zargis Medical Corp., a spin-off from Siemens Corporate Research (NYSE:
SI) and a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE),
announced that it has received U.S. Food and Drug Administration (FDA)
clearance to market its new Signal X6 device. Zargis also announced the
delivery of seven Signal X6 devices to the U.S. Army for deployment in six
Department of Defense medical facilities.

Signal X6 is noninvasive, easy to use and simultaneously records heart and
lung sounds from six adhesive sensors. The recordings can be evaluated
locally or, for locations where a cardiac specialist is not immediately
available for consultation, transmitted through the Internet for remote
evaluation. Signal X6 and our recently launched Zargis Cardioscan device
were both designed for user-friendly digital heart sound analysis. The
configuration of the Signal X6 provides a unique telemedicine resource in
situations where evaluations would benefit from high fidelity multi-channel
synchronous recordings.

"As healthcare systems continue to demand improved outcomes with
utilization of fewer resources, we believe that Signal X6 will provide
cost-effective, high quality cardiac analysis in situations where it`s not
practical for a patient to visit a specialist," said John Kallassy, Zargis`
CEO.

Prototypes for Signal X6 were first developed with funding from the
Telemedicine and Advanced Technology Research Center (TATRC) through the
AAMTI program. The AAMTI program provides funding to AMEDD personnel to
demonstrate technology and document the impact on cost, access and quality
of care. TATRC (www.tatrc.org) is an element of the United States Army
Medical Research and Materiel Command (USAMRMC).

ABOUT ZARGIS MEDICAL CORPORATION

Zargis Medical Corp. develops advanced diagnostic decision support
products and services for primary care physicians, pediatricians,
cardiologists and other healthcare professionals. Zargis was formed in 2001
when Siemens Corporate Research, a division of Siemens AG (NYSE: SI), and
Speedus Corp. co-invested to develop and market an advanced acoustic
technology designed to detect heart abnormalities identified through
analysis of heart sounds.

INTRAOP MEDICAL CORPORATION (OTCBB: IOPM)
"Up 20.59% in morning trading"

Detailed Quote: www.otcpicks.com/quotes/IOPM.php

IntraOp Medical Corporation provides innovative technology solutions for
the treatment and eradication of cancer. Founded in 1993, IntraOp is
committed to providing the tools doctors need to administer intraoperative
radiation therapy safely and effectively for all cancer patients. The
companys flagship product, the Mobetron, is the first fully portable,
self-shielding intraoperative electron radiation therapy device designed
for use in any operating room. Key Mobetron benefits include: increased
survival rates, better local tumor control, shorter treatment cycles,
immediate palliative effect, and fewer side effects. Leading hospitals,
from university research centers to specialized cancer clinics world-wide
are increasingly using the Mobetron to treat a wide variety of cancers as a
vital part of their comprehensive cancer program.

IOPM News:

September 15 - Groundbreaking Breast Cancer Radiation Technique Delivers
Proven Long-Term Benefits and Saves Lives

One minute of radiation in the operating room (OR) could save the lives of
thousands of women being treated for breast cancer in the US today.
According to a growing body of research, a 60-second course of radiation
therapy delivered during surgery dramatically improves results. But, until
recently, logistical and administrative difficulties prevented most
patients from receiving this crucial treatment until weeks after their
procedures.

Now, a portable, self-contained radiation therapy system, the Mobetron
from IntraOp Medical Corporation (OTCBB: IOPM) in Sunnyvale, Calif., is
changing all that. St. Joseph Hospital (Orange, Calif.), one of only 16
prestigious designated National Cancer Institute Community Cancer Centers,
this month introduced the first ongoing intraoperative electron radiation
therapy (IOERT) program for breast cancer. During lumpectomy surgery, St.
Josephs patients receive a high dose of therapy focused specifically on
the tumor site, known as a boost. Given the benefits, other
facilities are expected to follow suit.

Felix Sedlmayer, MD, one of the worlds leading IOERT researchers and
the principal investigator of IOERT boost trials conducted by six European
medical centers over the past decade, concluded that IOERT cut breast
cancer five year recurrence rates dramatically, from an average of 5% to
less than 1%.

If the IOERT boost were a standard technique in the US, every year,
more than 5000 breast cancer recurrences could have be avoided,
according to Roland Reitsamer, MD, a surgeon at the University of Salzburg,
where the technique has been studied extensively for the past decade. Each
one of those recurrences typically would result in a subsequent mastectomy,
which also would be avoided. A prestigious Lancet review of studies on
breast cancer found a 25% increase in 15 year survival for patients with no
recurrences at five years, suggesting that IOERT boost could have a
significant impact on the survival of thousands of women worldwide.

What Every Woman Should Know About Intraoperative Radiation

It seems a matter of common sense. Lumpectomy is typically followed by a
six-week course of radiation therapy to help eliminate any remaining
malignant cells. Treatment takes place at least four weeks after surgery
when the breast has healed. Because traditional, post-operative radiation
is delivered externally, it must pass through the body to reach diseased
areas, and healthy tissue may be damaged in the process. Additionally, once
surgery is complete, physicians no longer have direct access to the target
area to easily and precisely deliver radiation.

So why not begin the radiation treatment during the surgery itself This
would immediately target any remaining cancer cells, while allowing
complete access to the tumor area for greater precision in radiation
delivery. It also would spare radiation dose to surrounding tissue and
reduce the number of days a woman has to travel to a cancer center for
external treatment after surgery. In fact, at St. Joseph, IOERT will
shorten the course of post-operative radiation by seven to 10 days by
delivering the targeted boost dose prior to, rather than after, traditional
treatments.

The answer is that intraoperative radiation simply hasnt been
practical until now, explains John Powers, CEO for IntraOp. Without
the Mobetron, the treatment would mean equipping a special operating room
with a costly, unwieldy 18,000 pound linear accelerator to generate
radiation as well as a shielded radiation vault to protect staff from
repeated exposure to this radiation. This is just not feasible for most
hospitals.

The other alternative, Mr. Powers points out, has been transferring
patients under anesthesia with an open incision from the OR to a radiation
therapy center, typically located offsite. This significantly increases the
risk and duration of surgery and anesthesia. The result: despite its
enormous benefits, IOERT has rarely been used in the US for breast
patients.

However, IOERT has been heavily investigated in major European university
hospitals and is currently in use in more than a dozen facilities. This is
not surprising because historically the European medical system has been an
early adopter of promising new paradigms for breast cancer diagnosis and
treatment, including mammography, breast conserving lumpectomy and sentinel
node biopsy.

The Mobetron

Specifically optimized for IOERT, the IntraOp Mobetron incorporates a
range of technological innovations to make all the benefits of this
treatment realistic and practical for women and their doctors around the
world. The innovative system eliminates the risk, time, cost and complexity
of IOERT by enabling delivery in any standard OR.

Unlike conventional linear accelerators, the Mobetron is relatively
lightweight and can be wheeled among different OR locations. The Mobetron
requires no external radiation vault or bunker because patented
technologies eliminate most stray room radiation generated by conventional
accelerators and because of its patented self-shielding,

To operate the device, following tumor excision, a Mobetron applicator
tube is temporarily inserted into the breast to provide precise treatment
directly to the tumor bed. The Mobetron is positioned for radiation
delivery, and the one-minute treatment takes place.

HYTHIAM INCORPORATED (NASDAQ: HYTM)
"Up 18.71% in morning trading"

Detailed Quote:

Hythiam, Inc. provides through its Catasys subsidiary, specialized
behavioral health management services to health plans, employers and unions
through a network of licensed and company managed health care providers.
The Catasys substance dependence program was designed to address substance
dependence as a chronic disease. The program seeks to lower costs and
improve member health through the delivery of integrated medical and
psychosocial interventions in combination with long term care coaching,
including the proprietary PROMETA Treatment Program for alcoholism and
stimulant dependence. The PROMETA Treatment Program, which integrates
behavioral, nutritional, and medical components, is also available on a
private-pay basis through licensed treatment providers. Hythiam does not
practice medicine or manufacture, distribute, or sell any medications and
has no relationship with any manufacturers or distributors of medications
used in the PROMETA Treatment Program.

HYTM News:

September 17 - Hythiam Enters into Agreement with Ford Motor Company for
Catasys Integrated Substance Dependence Solution

Hythiam, Inc. (Nasdaq: HYTM) announced that the Company has entered into a
three year agreement with Ford Motor Company to provide the Catasys
integrated substance dependence solution to Fords hourly employees in
Michigan enrolled in the National PPO and who meet certain criteria.
Eligible employees struggling with alcoholism, stimulant and opiate
dependence will be covered under the program, which contains medical
interventions including naltrexone, Suboxone and the proprietary
PROMETA Treatment Program, and psychosocial and care coaching components
across 52 weeks. The Company will conduct direct outreach to enroll
qualified members, and will also work with UAW-Ford and Fords EAP
program to ensure the most beneficial treatment pathway for members.
Contractual revenues from the agreement are based on a combination of
monthly fees for the member population for Catasys, with additional monthly
fees for members enrolled into the Catasys program. Operational
implementation is expected to begin shortly, and the program is anticipated
to launch in the fourth quarter of 2009.

We are pleased by the level of support we received from UAW-Ford and
Fords management personnel, said Terren Peizer, Hythiams Chairman
and CEO. Our ability to engage and contract with employers and health
plans highlights the flexibility of our program to address substance
dependence challenges faced by diverse payors and their member populations.
We have realigned our company and developed Catasys for the managed care
market, and it is rewarding to have a new agreement that further publicly
validates our product and business model. Fords desire to improve
employee care and productivity demonstrates a significant opportunity for
health plans to provide their customers the Catasys solution. We look
forward to additional agreements over the coming months, and we remain
focused on providing effective solutions that enhance member care and
improve clinical outcomes, resulting in lower total health care costs. This
is especially important as payors face multiple challenges including the
recently passed mental health parity and addiction equity bill (Wellstone
Domenici Mental Health Parity and Addiction Equity Act of 2008), and
increasing budgetary constraints at a time of rising substance dependence
rates due to the current economic environment.

Various studies, research and other resources demonstrate that:

* Problems related to alcohol and drug abuse cost American businesses
roughly $81 billion in lost productivity each year.
* 77% of illicit drug users in the United States are employed.
* 500 million workdays are lost annually due to alcoholism.
* Up to 40% of industrial fatalities and 47% of industrial injuries can be
linked to alcohol use and alcoholism.
* Employees who use drugs are 3.6 times more likely to be involved in a
workplace accident and 5 times more likely to file a workers
compensation claim.
* Employees who use drugs are 2.2 times more likely to request early
dismissal or time off, 2.5 times more likely to have absences of eight days
or more, and 3 times more likely to be late for work.

Catasys is focused on improving member care and providing better clinical
outcomes in an effort to reduce overall health care costs. Catasys was
designed to manage substance dependence as a chronic disease, with a focus
on integration between evidence-based medical and psychosocial elements in
an outpatient setting, combined with care coaches who will guide and assist
members with long-term recovery. Catasys includes identification,
engagement, treatment, coaching and ongoing monitoring components directed
at providing members with a customized pathway to recovery. The delivery of
the programs medical and psychosocial components is conducted by a
trained specialty network of providers who are addiction specialists, and
who organize care with care coaches through Catasyss IT technology
platform. Catasys also conducts outreach to qualified members and
coordinates with client resources to enroll them in the program, including
a focus on reducing barriers to treatment.

ABOUT HYTHIAM AND CATASYS

Hythiam, Inc. provides through its Catasys subsidiary, specialized
behavioral health management services to health plans, employers and unions
through a network of licensed and company managed health care providers.
The Catasys substance dependence program was designed to address substance
dependence as a chronic disease. The program seeks to lower costs and
improve member health through the delivery of integrated medical and
psychosocial interventions in combination with long term care coaching,
including the proprietary PROMETA Treatment Program for alcoholism and
stimulant dependence. The PROMETA Treatment Program, which integrates
behavioral, nutritional, and medical components, is also available on a
private-pay basis through licensed treatment providers. Hythiam does not
practice medicine or manufacture, distribute, or sell any medications and
has no relationship with any manufacturers or distributors of medications
used in the PROMETA Treatment Program.

ORIGIN AGRITECH LIMITED (NASDAQ: SEED)
"Up 29.65% in morning trading"

Detailed Quote:

Founded in 1997 and headquartered in Beijing, Origin Agritech Limited is
Chinas leading, vertically-integrated agricultural technology company
specializing in agri-biotech research, development and production to supply
the growing populations of China. Origin develops, grows, processes, and
markets crop seeds to farmers throughout China and parts of Southeast Asia
via a network of approximately 3,800 first-level distributors and 65,000
second-level distributors and retailers. The hybrid seed industry is
estimated at US $2.5 billion and that is expected to double within the next
five years. The Company currently operates facilities in 30 of 32 provinces
in China. Since Origin launched its first entirely internally developed
seed in 2003, the Company has developed 26 proprietary corn seed products,
19 proprietary rice seed products, 5 proprietary cotton seed products and 4
proprietary canola seed products that are in commercial production and
distribution as of December 2008.

SEED News:

September 17 - Origin Agritech Limited Reaches Agreement for Novel
Glyphosate-Tolerance Gene

Worldwide Rights for Genetically Modified (GM) Corn, Soybean, Rice,
Cotton, and Canola products

Origin Biotechnology, a wholly-owned subsidiary of Origin Agritech Limited
(Nasdaq: SEED) announced it has reached an comprehensive, worldwide
agreement with the Institute of Microbiology of the Chinese Academy of
Sciences (CAS) and Sichuan Biotech Engineering, Limited. CAS and Sichuan
Biotech jointly own the rights to an internally developed gene which is
highly tolerant to glyphosate (herbicide). This glyphosate-tolerance gene,
demonstrated to be extremely effective in both laboratory and field
environments, is entirely new to the consumer markets in that it has never
been commercialized, and is protected by patents granted separately by
China and USA separately.

For the entire life of the patent, Origin Biotechnology will receive
exclusive rights to sell and develop corn, soybean, rice, cotton and canola
products that contain these technology traits worldwide, both in the
territory within China and outside of China. Origin Biotechnology will also
receive exclusive rights to sub-license to any third parties to sell and
develop corn, soybean, rice, cotton and canola products that contain these
traits and with application of patent technology worldwide in the territory
within China and outside of China. Origin Biotech will also receive the
rights to improve and further develop this glyphosate-tolerant gene.
Additionally, no change of control in the patent will have impact on the
validity of this agreement.

As a result of this landmark agreement for Origin, Chairman Gengchen Han
reiterated, Origin continues to demonstrate that it is the leading,
technology-focused crop seed company in China. Our goal remains consistent
to lead the industry by serving farmers with unique enabling technology
and services, producing and protecting higher crop yields. Our focus
remains in the production of higher quality seed products, whether
proprietary or licensed.

UPDATE OF ORIGIN GM PROGRAM

Phytase

Worlds first transgenic phytase corn is expected to be commercially
launched as the first genetically modified corn product in China. Phase 5
passage is expected near term pending a final stage approval from the
Ministry of Agriculture (MOA). Currently, phytase corn continues to remain
the only biotechnology corn product in Phase 5 of development in China.
Phytase is currently used as an additive essential for the growth and
development of all animals, and limits the amount of phosphorus waste in
the environment. Phytase, as an additive for animal feed, is mandatory in
Europe, Southeast Asia, South Korea, Japan, and Taiwan for environmental
purposes. The worldwide phytase potential market size is US$500 million
dollars, including US$200 million for China alone, according to the China
Feed Industry Study. The corn seed market in China is estimated at US$1
billion.

Glyphosate (Herbicide) Tolerance

Glyphosate tolerance has passed the intermediate testing phase (Phase 2)
and entered the environmental release testing phase (Phase 3). Worldwide,
the largest segment of the transgenic crop market has been herbicide
tolerant crops. Specifically, glyphosate tolerant crops have been widely
accepted in cotton, corn, and canola in North America. Introduced in the US
in 1998, the use of glyphosate tolerant corn grew from 950,000 acres in
1998 to 2.3 million acres in 1999 to 41 million acres in 2007, or at a
compounded annual growth rate of 51.9%, according to the US Department of
Agriculture. The rapid historical adoption rate indicates farmers find this
trait to be extremely valuable. The high level of adoption of these crops
by farmers has also caused the reduction in value of the remaining
herbicide market.

Since their introduction in 1996, over 75 million acres of genetically
engineered glyphosate-tolerant crops have been planted, making up 46% of
the corn, 80% of soybean acres, and 70% of cotton acres in the US. These
genetically engineered crops have been adopted by farmers because they are
perceived to offer significant economic benefits over conventional crop and
herbicide programs. The adoption of glyphosate-tolerant crops has reduced
costs for US farmers an estimated $1.2 billion. On the basis of recent
adoption rates by growers around the world, it appears that
glyphosate-tolerant crops will continue to grow in number and in hectares
planted.

Pest Resistance (Bt Corn)

Pest resistance (Bt Corn) has passed the intermediate testing phase (Phase
2)and entered the environmental release phase (Phase 3). In these phase 2
and 3 trials, these traits continue to perform as the best performing
traits for pest resistance throughout China.

Bt crops produce a protein toxic to specific insects used in areas with
high levels of infestations of targeted pests. Bt cotton, which controls
varieties of the budworm and bollworm, was planted on 59 percent of U.S.
cotton acreage and 75 percent of the Chinese cotton acreage in 2007.
Introduced in 1996 in the US, acreage of Bt corn has grown from 3.6 million
acres in 1999 to 44 million acres in 2007, or at a compounded annual growth
rate of 36.7%, according to the US Department of Agriculture. This Bt corn
variety was planted on 49 percent of U.S. corn acreage in 2007.

LIFELINE BIOTECHNOLOGIES INCORPORATED (OTC: LLBO)
"Up 18.00% in morning trading"

Detailed Quote:

Lifeline Biotechnologies, Inc. operates as a medical technology company in
the United States. Its technologies focus on prevention, early detection,
diagnosis, and quick recovery of various disease conditions. The company is
developing a non-imaging technology, known as the First Warning System,
which measures tissue activity for the early detection of breast cancer in
women.

LLBO News:

August 31 - Lifeline Biotechnologies Files Additional Patents on Its First
Warning System

Lifeline Biotechnologies, Inc. (OTC: LLBO) announced that it has filed
four additional patents on its First Warning System methods and
technology.

The First Warning System has been designed, developed and tested, a
process that assists in identifying abnormalities of the breast.

Jim Holmes, Lifelines CEO, said that We are extending patent
protection on our proprietary neural net diagnostic technologies with the
filing of three additional patent applications in the United States. These
filings relate to four essential elements in its system for analyzing
temperature readings of breast tissue to identify cancerous tissue. The
patents address the First Warning Systems method for the placement
of temperature sensors to obtain reliable temperature readings, its method
for analyzing the temperature readings, and its placeholder for assuring
proper sensor placement. In addition, a fourth application was filed under
the Patent Cooperation Treaty (PCT) to extend Lifeline Biotechnologies
protection, internationally, on all of the existing patent filings and
existing intellectual property including these new filings.

Lifeline Biotechnologies previously received two patents on its First
Warning System hardware and has in the past year filed for a patent on
the technological advancements of the First Warning System software.
The software has achieved the robust capability of identifying and
classifying tissue abnormalities of the breast with sensitivities (ability
to identify) of 95% to 100% and specificities (verify) of 87% to 90%.
Currently, it is widely recognized that mammograms miss an estimated 20 to
30% of the breast cancers.

Lifeline competes in the money markets for funds to continue the
development of its products as well as supporting operating and
administrative expenses. The cost of funds for companies such as Lifeline
is expensive and the terms have been, and may continue to be, dilutive. The
Company is seeking other means of financing in an effort to reduce the
dilutive aspects.

ALR TECHNOLOGIES INCORPORATED (OTCBB: ALRT)
"Up 22.22% in morning trading"

Detailed Quote:

The ALRT Health-E-Connect Disease Management System is designed to enhance
compliance of prescribed therapies and report diagnostic data from a number
of devices to health professionals for monitoring of patients. The System
facilitates cost effective continued oversight of patients by authorized
health professionals in-between visits to their physician.

ALRT News:

September 14 - Patent Application Approval for Remote Monitoring of
Patient`s Use of Nebulizer Compressors Facilitates Enhanced Coordination of
Care for Patients With Respiratory Disease

ALR Technologies (OTCBB: ALRT) announces that it has received notice from
the US Patent and Trademark Office that ALRT has been granted approval of
its patent application regarding patient compliance and remote monitoring
of patient`s use of nebulizer compressors. This approval from the US patent
office will protect ALRT`s Health-E-Connect health management
communications system and more importantly, will grant ALRT the exclusive
ability to remotely monitor the use of nebulizer compressors in the
delivery of medications to patients with COPD, chronic asthma and cystic
fibrosis.

COPD is one of the leading causes of death in the world. With 16 million
people in the US with COPD and 20 million plus with asthma, utilizing
ALRT`s Health-E-Connect system to monitor their use of nebulizer compressor
creates the opportunity to significantly improve quality of life and reduce
healthcare costs. Health Professionals will now be able to remotely monitor
and evaluate compliance in delivery of aerosolized medications to their
patients with respiratory diseases thereby helping these patients to reduce
health complications and improve their quality of life.

The use of monitoring-ready nebulizer compressors and ALRT`s
Health-E-Connect health management communications system can become an
important new service provided by health professionals. Furthermore, the
Health-E-Connect system is on target with the growing recognition in the US
to use electronic health records to improve the efficiency and
effectiveness of patient care.

ALRT announced earlier this year that insurance carriers will reimburse
physicians for the remote care of patients with the use of its
Health-E-Connect system. This will result in new revenue for physicians as
they provide the additional service to their patients with respiratory
disease. ALRT`s Health-E-Connect and complementary Constant Health
Companion is the only system in the US and International markets that
allows for remote monitoring of patients` use of nebulizer compressors.
This capability will allow for enhanced patient compliance and health
professional coordination of care.

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078,
Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address
is being protected from spam bots, you need Javascript enabled to view it.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS
REPORT. We are not registered as a securities broker-dealer or an
investment adviser either with the U.S. Securities and Exchange Commission
(the "SEC") or with any state securities regulatory authority. We are
neither licensed nor qualified to provide investment advice. OTCPicks.com
makes no recommendation that the purchase of securities of companies
profiled in this web site is suitable or advisable for any person or that
an investment such securities will be profitable. In general, given the
nature of the companies profiled and the lack of an active trading market
for their securities, investing in such securities is highly speculative
and carries a high degree of risk. You are receiving this email because you
have registered on OTCPicks.com or one of our affiliate companies.

The information contained in our report should be viewed as commercial
advertisement and is not intended to be investment advice. The report is
not provided to any particular individual with a view toward their
individual circumstances. The information contained in our report is not an
offer to buy or sell securities. We distribute opinions, comments and
information free of charge exclusively to individuals who wish to receive
them.

Our newsletter and website have been prepared for informational purposes
only and are not intended to be used as a complete source of information on
any particular company. An individual should never invest in the securities
of any company profiled based solely on information contained in our
reports. Individuals should assume that all information contained in the
report about profiled companies is not trustworthy unless verified by their
own independent research.

Any individual who chooses to invest in any securities should do so with
caution. Investing in securities is speculative and carries a high degree
of risk; you may lose some or all of the money that is invested. Always
research your own investments and consult with a registered investment
advisor or licensed stock broker before investing.

Information contained in our report will contain "forward looking
statements" as defined under Section 27A of the Securities Act of 1933 and
Section 21B of the Securities Exchange Act of 1934. Subscribers are
cautioned not to place undue reliance upon these forward looking
statements. These forward looking statements are subject to a number of
known and unknown risks and uncertainties outside of our control that could
cause actual operations or results to differ materially from those
anticipated. Factors that could affect performance include, but are not
limited to, those factors that are discussed in each profiled company`s
most recent reports or registration statements filed with the SEC. You
should consider these factors in evaluating the forward looking statements
included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are
profiled. However, we do not provide any assurance as to the accuracy or
completeness of the information provided, including information regarding a
profiled company`s plans or ability to effect any planned or proposed
actions. We have no first-hand knowledge of any profiled company`s
operations and therefore cannot comment on their capabilities, intent,
resources, nor experience and we make no attempt to do so. Statistical
information, dollar amounts, and market size data was provided by the
subject company and related public information sources which we believe to
be reliable but we cannot guarantee the accuracy of the information. To the
fullest extent of the law, we will not be liable to any person or entity
for the quality, accuracy, completeness, reliability, or timeliness of the
information provided in the report, or for any direct, indirect,
consequential, incidental, special or punitive damages that may arise out
of the use of information we provide to any person or entity (including,
but not limited to, lost profits, loss of opportunities, trading losses,
and damages that may result from any inaccuracy or incompleteness of this
information). We encourage you to invest carefully and read investment
information available at the websites of the SEC at
FINRA at

Disclosure: OTCPicks has been compensated two thousand five hundred
dollars from a non-controlling third party (BlueWave Advisors) for AEXP
advertising and promotional services. OTCPicks has been compensated ten
million free trading shares from a non-controlling third party (Microcap
Management) for DVME advertising and promotional services. OTCPicks has
been compensated ten thousand dollars from a non-controlling third party
(GREEN TECH INTERNATIONAL ADVISORS) for MDOR advertising and promotional
services. OTCPicks.com has been compensated four hundred thousand free
trading shares from a non-controlling third party for MPPC advertising and
promotional services. OTCPicks.com is being compensated eight thousand
dollars by a third party for MPPC advertising and promotional services.
OTCPicks.com is being compensated eight thousand dollars by a third party
(Mickey Reno) for EWRC advertising and promotional services. OTCPicks.com
has been compensated six thousand dollars by a third party (Mercom Capital)
for ALRT advertising and promotional services. This compensation
constitutes a conflict of interest as to our ability to remain objective in
our communication regarding the profiled company. OTCPicks.com is a website
partially owned by BlueWave Advisors, LLC, a financial public relations
firm. BlueWave Advisors, LLC, its principal and/or its affiliates will hold
positions in the company profiled and may buy or sell securities at any
time without notice.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has not been compensated by any of the companies covered in this release. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php . The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor`s entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company`s ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

Disclaimer: http://www.otcpicks.com/disclaimer.htm

Disclosure Details: http://www.otcpicks.com/disclosure-details.htm

CONTACT: Brian Dean, Publisher, OTCPicks.com
Tel: +1 972 546 3740
EMail : publisher@otcpicks.com

See OTC Picks's website for full disclaimer. OTC Picks may have received compensation for stock picks.